Serum metabolomics analysis revealed metabolic disorders in Parkinson’s disease

Abstract

Background: Parkinson’s disease (PD) is by now the second of the most prevalent neurodegenerative diseases in the world, and its incidence is increasing rapidly as the global population ages, with 14.2 million PD patients expected worldwide by 2040. Methods: We gathered a completion of 45 serum samples, including 15 of healthy controls and 30 from the PD group. We used non-targeted metabolomics analysis based on liquid chromatography-mass spectrometry to identify the molecular changes in PD patients, and conducted bioinformatics analysis on this basis to explore the possible pathogenesis of PD. Results: We found significant metabolomics changes in the levels of 30 metabolites in PD patients compared with healthy controls. Conclusion: Lipids and lipid-like molecules accounted for the majority of the 30 differentially expressed metabolites. Also, pathway enrichment analysis showed significant enrichment in sphingolipid metabolic pathway. These assessments can improve our perception on the underlying mechanism of PD as well as facilitate a better targeting on therapeutic interventions.

Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson’s Disease

“…Excessive ROS can inflict damage on all macromolecules, including lipids, proteins, and nucleic acids, as well as enzymes, leading to a significant decline in physiological activity. A metabolomic study by Lan et al [328] revealed a link between Parkinson's disease (PD) and dyslipidemia, suggesting that the stimulation of sphingolipid metabolic pathways may also contribute to PD etiology. Jacquemyn et al [329] emphasized the substantial role of lipids in PD genesis, highlighting connections between the functions of two genes associated with the disease through neural lipid metabolism.…”

Metabolomic profiling reveals altered phenylalanine metabolism in Parkinson’s disease in an Egyptian cohort

“…Another non-targeted metabolomics study on 39 preclinical PD patients study showed alterations in 33 metabolites’ levels, including significant reductions in the levels of the free fatty acids (FFAs), suggesting alterations in FFAs metabolism, oxidative stress, and mitochondrial dysfunction; these results were further validated by a targeted HPLC-QqQ-Ms approach ( Gonzalez-Riano et al, 2021 ). A recent study using non-targeted metabolomics analysis on 30 PD patients revealed alterations in the levels of 30 metabolites, including the metabolism of lipids and lipid-like molecules ( Lan et al, 2023 ).…”